T Cell–Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant Disease
Open accessThe DOI matches its Crossref record.
Abstract
Purpose: Cyclin B1–derived peptides were shown by us to be targets of tumor-specific CD8+ T cells in patients with breast and head and neck cancer. We obtained further evidence of cyclin B1 immunogenicity and its potential to serve as a tumor-specific antigen by analyzing its ability to elicit T cell–dependent humoral immune responses in vivo in patients with different types of tumors. Experimental Design: Recombinant cyclin B1 protein from two different sources was purified and used as antigen in ELISA assays to test sera from patients with breast, pancreatic, colon, and lung cancer for the presence of anti-cyclin B1 antibody. We also analyzed patients with benign lung disease, premalignant disease, and a known history of heavy smoking. Results and Conclusions: Cyclin B1 elicits helper T cell–dependent antibody responses in vivo. Tumors with higher level of cyclin B1 expression elicit higher anti-cyclin B1 antibody levels. Antibodies in patients with breast and colon cancer are primarily of the IgG isotype whereas patients with pancreatic and lung cancer have in addition anti-cyclin B1 IgA. Cyclin B1–specific IgG was also detected in long-term smokers and in patients with preneoplastic lung disease. Immune responses to aberrantly expressed cyclin B1 in tumors and premalignant lesions should be further explored as diagnostic and prognostic markers, in addition to their immunotherapeutic potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
Finn, O. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072739 · Cited by 774
Self-citationSerum autoantibodies as biomarkers for early cancer detection
Tan, H. T., Low, J., Lim, S. G., & Chung, M. C. M. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07396.x · Cited by 315
The Sentinel Within: Exploiting the Immune System for Cancer Biomarkers
Anderson, K. S., & LaBaer, J. (2005) · Journal of Proteome Research · doi:10.1021/pr0500814 · Cited by 314
Autoantibodies to tumor‐associated antigens: reporters from the immune system
Tan, E. M., & Zhang, J. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00611.x · Cited by 309
Metadata
- Authors
- Suzuki, H., Graziano, D. F., McKolanis, J., & Finn, O. J.
- Venue
- Clinical Cancer Research
- Published
- 2005-02-15
- Volume
- 11
- Issue
- 4
- Pages
- 1521-1526
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2121779244
- Cited by
- 113
- References
- 0
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: T Cell–Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant Disease. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-0538
- The paper
- Suzuki, H., Graziano, D. F., McKolanis, J., & Finn, O. J. (2005). T Cell–Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant Disease. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-0538
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.